Gilead, Teva settle fight over HIV drug Viread
This article was originally published in Scrip
Executive Summary
After three years of legal wrangling, Gilead Sciences said it agreed to settle a dispute with Teva Pharmaceuticals, allowing the generic drug maker to market its own version of the HIV drug Viread just weeks before the treatment loses US patent protection in 2017.